The same year, an estimated 10.6 million people fell ill with TB all over the world. The multidrug-resistant TB (MDR-TB) is therefore a public health crisis and an additional health security threat. The IMI-RespiriTB RespiriNTM project, funded by the European Union and Johnson & Johnson to tackle Mycobacterium tuberculosis, entered its fourth year in 2023 (see the related RespiriTB RespiriNTM LinkedIn LinkedIn post).
Mitologics is happy to contribute with its know-how in predictive toxicology to this exciting collective effort to come out with a new set of anti-TB drugs. We are looking forward to further progress in 2024!